STERIS plc is set to release earnings information with anticipation building among investors. A number of institutional investors have raised their stakes in STERIS, including Fiduciary Family Office LLC, Turning Point Benefit Group Inc., and Mutual of America Capital Management LLC. However, others like Allianz Asset Management GmbH and Copeland Capital Management LLC have reduced their shares. Notably, STERIS CEO Daniel Carestio recently sold a notable amount of shares.
The company has found support from analysts, with consensus recommendations being a 'Moderate Buy'. Moreover, analysts are predicting a growth potential and significant upside in both the Medical Devices and Healthcare Sectors. Several key investments, including 111 Capital and Callan Family Office LLC's new investments, suggest a strong belief in the company's long-term potential.
The company has reported strong revenue growth and updated their financial outlook after beating Q1 earnings and revenue. It also raised the 2026 sales view. A new CFO is set to lead the company moving forward. Michael J. Tokich will be succeeded by Karen L. Burton. With growth driven by MedTech Momentum, STERIS's stock performance is seeing a decent run, and is expected to sustain its growth.
Steris Plc STE News Analytics from Sat, 26 Apr 2025 07:00:00 GMT to Fri, 24 Oct 2025 08:58:11 GMT - Rating 9 - Innovation 6 - Information 7 - Rumor 4
